Emergent BioSolutions
Also known as: EMERGENT | EMERGENT BIODEFENSE | Emergent BioDefense Operations Lansing LLC | Emergent BioSolutions | Emergent Biosolutions Canada Inc. | Emergent BioSolutions Canada Inc. | Emergent Biosolutions, Inc. | Emergent BioSolutions Inc | Emergent Clinical Consulting | Emergent Manufacturing Operations Baltimore LLC | Emergent Product Development Gaithersburg | Emergent Product Development Gaithersburg, Inc. | Emergent Product Development Seattle LLC | Emergent Travel Health, Inc.
Highest phase reached
Phase 3
First clinical trial
Sep 1, 2002First marketed drug
Jan 1, 1998First NDA
Nov 12, 1998Last known activity
Jul 20, 2023
Timeline
1990s
- Jan 1, 1998
Emergent BioSolutions— Founded
2010s
- Jan 1, 2010
Trubion Pharmaceuticals— Acquired
- Dec 14, 2012
raxibacumab— NDA Secondary Org
- Jan 1, 2013
Cangene— Acquired
- Aug 29, 2018
Adapt— Acquired
- Oct 1, 2018
PaxVax, Inc.— Acquired
2020s
- Jun 4, 2021
brincidofovir— NDA Organization
- Jun 4, 2021
brincidofovir— Marketing Organization
Drugs by trial phase (51 distinct, 61 trials)
Phase 4 (0 own, 4 via acquisition)
Phase 3 (2 own, 3 via acquisition)
Phase 2 (11 own, 5 via acquisition)
Phase 1 (13 own, 12 via acquisition)
Other trials (0 own, 1 via acquisition)
Indications
Studied for
- Anthrax
- Arthritis
- Arthritis, Rheumatoid
- Constriction, Pathologic
- Glomerulonephritis, Membranous
- Infections
- Influenza, Human
- Kidney Diseases
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lupus Erythematosus, Systemic
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Mycoses
- Mycosis Fungoides
- Sezary Syndrome
- Spinal Stenosis
- Spondylolisthesis
- Syndrome
- Tuberculosis
- Typhoid Fever
- Virus Diseases
- Zika Virus Infection
Marketed drugs (13)
Subsidiaries (4 direct, 4 total across the full acquisition tree)
Recent trials (50)
- NCT05935917Lead sponsorPhase 1May 30, 2023
- NCT05377255Study directorPhase 1Mar 28, 2022
- NCT05377255Lead sponsorPhase 1Mar 28, 2022
- NCT05142306Study directorPhase 1Dec 31, 2021
- NCT05142306Lead sponsorPhase 1Dec 31, 2021
- NCT05194358Lead sponsorPhase 1Dec 21, 2021
- NCT05155319Lead sponsorPhase 1Dec 1, 2021
- NCT05155319Study directorPhase 1Dec 1, 2021
- NCT05065983Lead sponsorPhase 2Oct 11, 2021
- NCT05065983Study directorPhase 2Oct 11, 2021
- NCT05072080Study directorPhase 3Sep 29, 2021
- NCT05072080Lead sponsorPhase 3Sep 29, 2021
- NCT04661839Lead sponsorPhase 1Dec 31, 2020
- NCT04483297CollaboratorPhase 1Oct 31, 2020
- NCT04067011Lead sponsorPhase 2Aug 12, 2019
Details
- Founded
- Rockville, MD, US Jan 1, 1998
- First NDA
- Nov 12, 1998
- Last known activity
- Jul 20, 2023
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy